Zeitschrift fur Rheumatologie最新文献

筛选
英文 中文
Revisiting James Joyce's disease: insights into reactive arthritis vs. tertiary syphilis. 重新审视詹姆斯·乔伊斯的疾病:对反应性关节炎与三期梅毒的见解。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2026-03-09 DOI: 10.1007/s00393-026-01806-4
Luca Ventura
{"title":"Revisiting James Joyce's disease: insights into reactive arthritis vs. tertiary syphilis.","authors":"Luca Ventura","doi":"10.1007/s00393-026-01806-4","DOIUrl":"10.1007/s00393-026-01806-4","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"329-330"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidenz und klinische Rolle der transarteriellen periartikulären Embolisation (TAPE). 经动脉周关节栓塞(TAPE)的证据和临床作用。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2026-03-12 DOI: 10.1007/s00393-026-01792-7
Alexander Pfeil, Carolin Pflug, Gunter Wolf, René Aschenbach, Ulf Teichgräber
{"title":"Evidenz und klinische Rolle der transarteriellen periartikulären Embolisation (TAPE).","authors":"Alexander Pfeil, Carolin Pflug, Gunter Wolf, René Aschenbach, Ulf Teichgräber","doi":"10.1007/s00393-026-01792-7","DOIUrl":"10.1007/s00393-026-01792-7","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"333-335"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cardiovascular risk in inflammatory rheumatic diseases : Evidence-based strategies for risk reduction in rheumatologic practice]. [风湿性疾病的心血管风险:风湿病实践中降低风险的循证策略]。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2026-04-08 DOI: 10.1007/s00393-026-01800-w
Stefan Kleinert
{"title":"[Cardiovascular risk in inflammatory rheumatic diseases : Evidence-based strategies for risk reduction in rheumatologic practice].","authors":"Stefan Kleinert","doi":"10.1007/s00393-026-01800-w","DOIUrl":"10.1007/s00393-026-01800-w","url":null,"abstract":"<p><p>Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have a persistently increased cardiovascular (CV) risk and higher mortality, independently of traditional CV risk factors. Effective control of inflammation reduces CV events, whereas glucocorticoids increase the risk in a dose- and duration-dependent manner, even at ≤ 5 mg prednisolone/day. Disease-modifying antirheumatic drugs especially tumor necrosis factor (TNF) inhibitors, are largely protective through the reduction of systemic inflammation. For patients receiving Janus kinase (JAK) inhibitors or long-term glucocorticoid therapy, a structured CV risk assessment and guideline-based management of modifiable risk factors (including lipid optimization/statin therapy) are essential. Primary prevention should be based on the cardiovascular prevention guidelines of the European Society of Cardiology (ESC). Vaccinations (influenza, COVID-19, pneumococcus, respiratory syncytial virus, zoster) represent an effective pillar of CV prevention in populations at cardiovascular risk; however, evidence in patients with inflammatory rheumatic diseases is still lacking. The main challenge for CV prevention remains implementation: digital clinical reminders/decision support systems and multicomponent strategies can improve the implementation of recommendations.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"307-316"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitteilungen der DRL. DRL通讯。
IF 1 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 DOI: 10.1007/s00393-026-01819-z
{"title":"Mitteilungen der DRL.","authors":"","doi":"10.1007/s00393-026-01819-z","DOIUrl":"https://doi.org/10.1007/s00393-026-01819-z","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":"85 4","pages":"339"},"PeriodicalIF":1.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Professional situation of rheumatological specialist assistants (RFA, DGRh-BDRh) after training : Results of a nationwide survey in 2024]. [风湿病专科助理(RFA, DGRh-BDRh)培训后职业状况:2024年全国调查结果]。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2026-01-28 DOI: 10.1007/s00393-026-01777-6
Florian Schuch, Klaus Krüger, Anna Voormann, Dorothea John, Luisa Martens, Kirsten Hoeper
{"title":"[Professional situation of rheumatological specialist assistants (RFA, DGRh-BDRh) after training : Results of a nationwide survey in 2024].","authors":"Florian Schuch, Klaus Krüger, Anna Voormann, Dorothea John, Luisa Martens, Kirsten Hoeper","doi":"10.1007/s00393-026-01777-6","DOIUrl":"10.1007/s00393-026-01777-6","url":null,"abstract":"<p><p>Since the introduction of the qualification for rheumatological specialist assistants (RFA) by the German Society for Rheumatology (DGRh) and the Professional Association of German Rheumatologists (BDRh) in 2006, this advanced training has become an established component of rheumatological care. Although more than 2000 medical assistants have since completed the RFA qualification, only limited data have been available on their professional situation after completion of the program. The aim of the present nationwide online survey was to assess the current professional situation, areas of activity, job satisfaction and career paths of RFAs in Germany.In October 2024 all graduates from 2006-2024 known to the Rheumatism Academy (Rheumaakademie, n = 677) were invited via email. A total of 263 individuals completed the questionnaire (response rate 39%), of whom 243 provided complete responses.At the time of the survey 81% (n = 199/245) of respondents were still working as RFAs, mostly in rheumatology practices (71%). Independent RFA consultation hours were conducted by 44% (n = 86) of participants, with most offering their own appointments, using defined procedures and having separate consultation rooms available. The main reasons cited for leaving RFA work were high workload, lack of development opportunities, and insufficient recognition. Nevertheless, 96% of those who had left the RFA role remained employed in the medical field.The results show that the RFA has become firmly established as a key component of rheumatological care in Germany; however, due to voluntary participation and limited reachability of all graduates, selection bias is likely and particularly RFAs no longer working in the profession may be underrepresented.To sustainably strengthen and retain this professional group, structural improvements are necessary, especially legal clarification of delegable tasks, the establishment of reimbursement options for RFA consultation hours and the development of advanced qualifications and career pathways.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"324-328"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146067530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitteilungen der DGRh – Veranstaltungen der Rheumaakademie. “DGRH - RheumaAkademie事件”。
IF 1 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 DOI: 10.1007/s00393-026-01818-0
{"title":"Mitteilungen der DGRh – Veranstaltungen der Rheumaakademie.","authors":"","doi":"10.1007/s00393-026-01818-0","DOIUrl":"https://doi.org/10.1007/s00393-026-01818-0","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":"85 4","pages":"338"},"PeriodicalIF":1.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KI beim Publizieren: Was Ärzt*innen wissen und konkret beachten sollten. 医生应该知道什么,医生应该做什么。
IF 1 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 DOI: 10.1007/s00393-026-01817-1
Ines Wolff, Henning Schönenberger
{"title":"KI beim Publizieren: Was Ärzt*innen wissen und konkret beachten sollten.","authors":"Ines Wolff, Henning Schönenberger","doi":"10.1007/s00393-026-01817-1","DOIUrl":"https://doi.org/10.1007/s00393-026-01817-1","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":"85 4","pages":"259-261"},"PeriodicalIF":1.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Kikuchi-Fujimoto disease: case report of a 32-year-old woman with lymphadenopathy and fever]. [菊池-藤本病:32岁女性伴淋巴结病和发热1例报告]。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2025-09-08 DOI: 10.1007/s00393-025-01725-w
Aiman Gamal Abdelrahim, Julian Schulze Zur Wiesch, Ulrike Schnoor, Stefan Schmiedel
{"title":"[Kikuchi-Fujimoto disease: case report of a 32-year-old woman with lymphadenopathy and fever].","authors":"Aiman Gamal Abdelrahim, Julian Schulze Zur Wiesch, Ulrike Schnoor, Stefan Schmiedel","doi":"10.1007/s00393-025-01725-w","DOIUrl":"10.1007/s00393-025-01725-w","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"320-323"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wirkung und Stellenwert der Radiosynoviorthese im Behandlungskonzept entzündlicher Gelenkerkankungen. 放射治疗在治疗炎症性关节癌中的作用和重要性。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2026-03-12 DOI: 10.1007/s00393-026-01791-8
Willm Uwe Kampen, Lutz S Freudenberg, Knut Liepe, Barbara Boddenberg-Pätzold, Norbert Czech, Christoph Neumann-Glück, Rigobert Klett, Manfred Fischer
{"title":"Wirkung und Stellenwert der Radiosynoviorthese im Behandlungskonzept entzündlicher Gelenkerkankungen.","authors":"Willm Uwe Kampen, Lutz S Freudenberg, Knut Liepe, Barbara Boddenberg-Pätzold, Norbert Czech, Christoph Neumann-Glück, Rigobert Klett, Manfred Fischer","doi":"10.1007/s00393-026-01791-8","DOIUrl":"10.1007/s00393-026-01791-8","url":null,"abstract":"","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"331-332"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a meta-analysis of randomized trials. belimumab与anifrolumab治疗系统性红斑狼疮和狼疮性肾炎的间接比较疗效和安全性:随机试验的荟萃分析。
IF 1.2 4区 医学
Zeitschrift fur Rheumatologie Pub Date : 2026-05-01 Epub Date: 2025-12-04 DOI: 10.1007/s00393-025-01760-7
Young Ho Lee, Gwan Gyu Song
{"title":"Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a meta-analysis of randomized trials.","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.1007/s00393-025-01760-7","DOIUrl":"10.1007/s00393-025-01760-7","url":null,"abstract":"<p><strong>Objective: </strong>Belimumab and anifrolumab are two biologic therapies currently employed in the management of systemic lupus erythematosus (SLE). Belimumab is approved for both SLE and lupus nephritis (LN), whereas anifrolumab is not currently approved for LN and has only been evaluated for LN in one published phase II trial. Direct head-to-head comparative data are lacking. This meta-analysis aims to indirectly compare the efficacy and safety of belimumab and anifrolumab using evidence from randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>We performed a comprehensive search of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. Indirect comparative analyses were conducted using odds ratios (ORs) and hazard ratios (HRs) derived from clinical trial data comparing both belimumab and anifrolumab with placebo for SLE and LN. Primary endpoints included SRI‑4 response, SELENA-SLEDAI ≥ 4 reduction, corticosteroid dose reduction, incidence of severe flares, normalization of anti-dsDNA, and normalization of C3/C4 in SLE as well as complete renal response (CRR), renal event-free survival, and immunologic biomarkers in LN. Safety was evaluated based on the incidence of herpes zoster, serious infections, and mortality.</p><p><strong>Results: </strong>Seven RCTs comprising 4332 patients treated with either belimumab or anifrolumab for SLE or LN were included in this meta-analysis. For SLE, belimumab demonstrated superior SRI‑4 response rates (OR = 1.99, 95% CI: 1.25-3.16) relative to anifrolumab, whereas anifrolumab yielded greater benefit in steroid tapering (OR = 0.31, 95% CI: 0.19-0.51) and immunologic normalization (anti-dsDNA: OR = 0.69, 95% CI: 0.43-1.10; C3/C4: OR = 0.69, 95% CI: 0.42-1.13). In LN, both agents improved CRR rates compared to placebo; however, indirect comparisons between the two agents were not definitive due to wide confidence intervals (CRR: OR = 0.83, 95% CI: 0.22-3.10). Safety profiles were similar in terms of serious infections and mortality, although anifrolumab was linked to higher rates of herpes zoster (7.2% vs. 3.2-4.6% for belimumab).</p><p><strong>Conclusion: </strong>Belimumab confers greater benefit in terms of SRI‑4 response for SLE, while anifrolumab is more effective for corticosteroid tapering and immunologic parameter normalization. In LN, the comparative efficacy remains uncertain. Both agents exhibit similar safety profiles, but anifrolumab is associated with an increased risk of herpes zoster. Differences in study design, inclusion criteria, and assessment protocols among included trials may limit direct comparability.</p>","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"298-306"},"PeriodicalIF":1.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书